DOSE-FINDING STUDY TO ASSESS THE SAFETY AND EFFECT OF SYL1001 IN PATIENTS WITH OCULAR PAIN
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2016
At a glance
- Drugs Tivanisiran (Primary)
- Indications Ocular pain
- Focus Therapeutic Use
- Sponsors Sylentis
- 04 Apr 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Mar 2016 Results and additional analysis of this clinical trial will be presented at the ARVO conference in May 2016, according to a Sylentis media release.
- 14 Mar 2016 Results published in a Sylentis media release.